Oncogenex makes SATURN trial of custirsen (OGX-011) more accessible

The Phase III SATURN clinical trial of OGX-011 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after initial chemotherapy with docetaxel + prednisone required men to be randomized to either docetaxel + prednisone + OGX-011 or to docetaxel + prednisone + a placebo. … READ MORE …

Prostate cancer news reports: Monday, July 26, 2010

There are several interesting new publications worth commenting on this morning — all in the evolving research field as opposed to current clinical practice:

  • Angiogenic effect of a specific statin on prostate cancer development
  • Synergistic impact of calcitriol on cryotherapy
  • Hybrid imaging techniques and prostate cancer
  • GTI-2040 in treatment of CRPC … READ MORE …